Seres Therapeutics Inc — Cash Flow (NASDAQ:MCRB) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -93.61 M6.69 M-228.82 M-117.35 M-148.61 M1.12 M 1.12 M Cash from investing activities -158.89 M64.09 M82.43 M10.58 M142.29 M-42 K -42 K Cash from financing activities 303.42 M1.18 M129.6 M71.7 M-90.37 M13.9 M 13.9 M Free cash flow -94.2 M-2.88 M-238.64 M-125.33 M-148.99 M865 K 865 K

News

Seres Therapeutics schedules 2026 annual meeting for June 9

Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript

Seres stock falls after pausing Phase 2 study and cutting workforce by 30%

Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'

Seres Therapeutics publishes new insights on VOWST mechanism

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as director

Seres to present new data on SER-155 bloodstream infection study

Seres Therapeutics announces workforce reduction to extend cash runway

Factbox-More companies adopt co-CEO structure

Canaccord Genuity raises Seres Therapeutics stock price target to $22 on FDA hopes

Seres Therapeutics advances SER-155 protocol after FDA feedback